Currently, there are no disease-modifying, regenerative or neuroprotective treatments for Parkinson's disease (PD). A European clinical trial will test a regenerative therapy for PD that will promote endogenous brain repair mechanisms.
PD is a chronic and progressive neurological disorder, affecting over a million Europeans. It is associated with degeneration of the dopamine-producing nerve cells in the substantia nigra in the brain. Current pharmacological therapies for PD carry side-effects and become less effective as the disease progresses. Regenerative therapy would revolutionise the capacity to effectively treat PD patients and could dramatically reduce the annual multi-billion treatment costs.
Further details: Towards regenerative therapy for Parkinson's disease